Crispr Therapeutics AG CRSP
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
Revenue compounded at +37.3% a year over the five years to FY2025.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Each USD of equity lost 30 cents this year.
The 12-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.4 | 0.0 | 0.9 | 0.0 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | ◌ |
| Operating income $B | −0.7 | −0.5 | −0.2 | −0.7 | 0.4 | −0.4 | 0.0 | −0.2 | −0.1 | −0.1 | −0.0 | −0.0 |
| EBITDA $B | −0.6 | −0.4 | −0.2 | −0.6 | 0.4 | −0.3 | 0.1 | −0.2 | −0.1 | −0.1 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 |
| Net income $B | −0.6 | −0.4 | −0.2 | −0.7 | 0.4 | −0.3 | 0.1 | −0.2 | −0.1 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.3 | −0.1 | −0.3 | −0.5 | 0.5 | −0.3 | 0.0 | −0.1 | −0.1 | −0.1 | 0.1 | ◌ |
| EPS, diluted $ | −6.47 | −4.34 | −1.94 | −8.36 | 4.70 | −5.29 | 1.17 | −3.44 | −1.71 | −1.89 | −5.06 | 1.97 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE % | −30.2 | −19.2 | −8.2 | −30.4 | 18.6 | −26.8 | 10.0 | −56.9 | −32.5 | — | — | — |
| Shares out B | 0.10 | 0.09 | 0.08 | 0.08 | 0.08 | 0.07 | 0.06 | 0.05 | 0.04 | 0.04 | 0.01 | ◌ |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 12 of the 12 fiscal years we could check. 16 checks were skipped: the balance sheet is not tagged before 2015. Seven checks were skipped: EPS is not tagged before 2014.